Drug intelligence / Profile preview

QLM3004

Development stage: Phase 3
Lead developer: Qilu Pharmaceutical
Modality: Small Molecules
Administration: Ophthalmic

Overview

QLM3004 is an investigational small molecule ophthalmic drop being developed by Qilu Pharmaceutical for the treatment of myopia. It is currently in phase 3 clinical trials in China, where it is being evaluated for its efficacy and safety in slowing the progression of myopia in children aged 6 to 12 years. The precise mechanism of action has not been disclosed[1][2][3][4].

Beyond the preview

Go deeper on QLM3004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLM3004.

Explore the full profile